Overview

JS001sc or JS001 Plus Chemotherapy is Indicated for Relapsed or Metastatic First-Line Non-Squamous Non Small Cell Lung Cancer（NSCLC）

Status:
ACTIVE_NOT_RECRUITING

Trial end date:
2026-12-30

Target enrollment:

Participant gender:

Summary

This is a multicenter, open-Lable, randomized, phase III clinical study to compare the pharmacokinetic profile, efficacy, and safety of Toripalimab injection (subcutaneous) (JS001sc) and Toripalimab injection (JS001) in combination with standard chemotherapy as first-line treatment for recurrent or metastatic Non-Squamous Non small cell lung cancer

Phase:

PHASE3

Details

Lead Sponsor:

Shanghai Junshi Bioscience Co., Ltd.

Collaborator:

Sponsor GmbH

Treatments:

Infusions, Intravenous
Injections, Subcutaneous
Pemetrexed